First Horizon Corporation’s BridgeBio Pharma BBIO Stock Holding History

First Horizon Corporation’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.6K	Sell	652 -800	-55%	-$56K	﹤0.01%	700
2026 Q1	$108K	Sell	1,452 -85	-6%	-$6.16K	﹤0.01%	483
2025 Q4	$118K	Buy	1,537 +843	+121%	+$55.3K	0.01%	485
2025 Q3	$36K	Buy	+694	New	+$33.8K	﹤0.01%	689

Other funds holding BBIO

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

WMA

Wealth Management Associates Cherry Hill, New Jersey $362M AUM 33.28% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

FBT

First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return

First Horizon Corporation's BBIO Position: Q2 2026 in Review

First Horizon Corporation reduced its BridgeBio Pharma (BBIO) stake by 55% in Q2 2026, selling an estimated $56K and leaving 652 shares worth $48.6K. The position accounts for ﹤0.01% of the portfolio, ranked #700.

First Horizon Corporation first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $118K in Q4 2025. 56 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

First Horizon Corporation held 652 shares of BridgeBio Pharma worth $48.6K as of Q2 2026.
First Horizon Corporation sold 800 BridgeBio Pharma shares in Q2 2026, an estimated $56K.
BridgeBio Pharma made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2026, its #700 holding.
First Horizon Corporation first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
First Horizon Corporation's BridgeBio Pharma position peaked at $118K in Q4 2025.
56 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on First Horizon Corporation's 13F filing for Q2 2026, filed 20 Jul 2026.